A1M Pharma has initiated a collaboration with Antaros Medical to conduct a study in humans undergoing radiation therapy (Peptide Receptor Radionuclide Therapy, PRRT) of neuroendocrine tumours. The purpose of the study is to examine - using magnetic resonance imaging (MRI) and positron emission tomography (PET) - the harmful effects that the radiation in PRRT has on the kidneys and the bone marrow. Data from the study will form the basis of the company's upcoming clinical studies. The study will be conducted at the Uppsala University Hospital, on patients that are treated with the targeted radiation therapy PRRT. The radiation therapy puts a strain on the patient's kidneys, with the risk of kidney injuries at a later stage. Today, kidney injuries and bone marrow injuries are the limiting factors of the maximum radiation dose that can be used during the radiation treatment, as well as the frequency of the treatments. On several occasions during the study, the patients will be examined with a magnetic resonance (MRI) and PET scanner for quick detection of changes in the organs occurring during the radiation therapy. The study is scheduled to start during the first quarter of 2018, and it is expected to be completed in last quarter of 2019.